Gerber Kawasaki Wealth & Investment Management Sells 3,473 Shares of Zoetis Inc. (NYSE:ZTS)

Gerber Kawasaki Wealth & Investment Management decreased its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 23.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,344 shares of the company's stock after selling 3,473 shares during the quarter. Gerber Kawasaki Wealth & Investment Management's holdings in Zoetis were worth $1,848,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. Aquatic Capital Management LLC bought a new position in Zoetis during the 4th quarter valued at $2,553,000. Oxford Asset Management LLP bought a new position in Zoetis during the 4th quarter valued at $974,000. Wills Financial Group Inc. lifted its stake in Zoetis by 5.4% during the 4th quarter. Wills Financial Group Inc. now owns 21,399 shares of the company's stock valued at $3,487,000 after acquiring an additional 1,102 shares in the last quarter. Coldstream Capital Management Inc. lifted its stake in Zoetis by 3.8% during the 4th quarter. Coldstream Capital Management Inc. now owns 34,482 shares of the company's stock valued at $5,618,000 after acquiring an additional 1,278 shares in the last quarter. Finally, Capital Analysts LLC lifted its stake in Zoetis by 5.5% during the 4th quarter. Capital Analysts LLC now owns 57,713 shares of the company's stock valued at $9,403,000 after acquiring an additional 3,025 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Up 0.8 %

Shares of Zoetis stock traded up $1.22 during trading on Wednesday, hitting $156.65. The company's stock had a trading volume of 2,926,140 shares, compared to its average volume of 2,484,978. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33. The company has a fifty day simple moving average of $158.81 and a two-hundred day simple moving average of $167.98. The company has a market capitalization of $69.89 billion, a PE ratio of 28.64, a P/E/G ratio of 2.78 and a beta of 0.92. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Equities research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.28%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis's payout ratio is 36.56%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ZTS. StockNews.com upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. Stifel Nicolaus decreased their target price on Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a research report on Monday, April 14th. Morgan Stanley dropped their price target on Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. Piper Sandler upped their price target on Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a research report on Thursday, February 27th. Finally, Barclays upped their price target on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research report on Friday, February 14th. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, Zoetis currently has an average rating of "Buy" and a consensus target price of $214.40.

Insider Buying and Selling

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of the firm's stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. This trade represents a 9.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Roxanne Lagano sold 326 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the sale, the executive vice president now owns 15,781 shares in the company, valued at approximately $2,682,770. The trade was a 2.02 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,862 shares of company stock valued at $312,254. 0.16% of the stock is owned by insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.